Bladder EpiCheck in high risk population
Main Authors: | P.F. Bassi, L. Gianfrancesco, M. Ragonese, G. Palermo, F. Pierconti, M. Martini, M. Racioppi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | European Urology Open Science |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168320300914 |
Similar Items
-
The diagnostic accuracy of Bladder EpiCheck in high-risk population
by: M. Racioppi, et al.
Published: (2020-07-01) -
The role of bladder EpiCheck test in follow-up of patients with NMBC recently treated with endovesical therapy
by: M. Ragonese, et al.
Published: (2020-10-01) -
The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence
by: Mariangela Mancini, et al.
Published: (2020-09-01) -
Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
by: Marco Racioppi, et al. -
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
by: Marco Racioppi, et al.
Published: (2018-12-01)